drugset / Trial / NCT00191841

Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

NCT00191841 ↗

Phase 2 Completed 50 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC

Timeline

Start
2002-12
Primary completion
—
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 —
Subject Gemcitabine Small molecule 1000 mg/m2 —